QUESTCOR PHARMACEUTICALS 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Date of Report (Date of earliest event reported): March 9, 2005
QUESTCOR PHARMACEUTICALS, INC.
3260 Whipple Road Union City, California 94587
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
On March 9, 2005, Questcor Pharmaceuticals, Inc. (the Company) announced via press release its results for the quarter and year ended December 31, 2004. A copy of the Companys press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On March 3, 2005, R. Jerald Beers, Vice President of Sales and Marketing, resigned from his position with the Company.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.